Drug Trial Radar · NCT04305041
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jun 26, 2020
Primary completion
Aug 25, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.
Conditions
- Melanoma
Interventions
PembrolizumabBiological
Administered via IV infusion at a specified dose on specified days
QuavonlimabBiological
Administered via IV infusion at a specified dose on specified days
VibostolimabBiological
Administered via IV infusion at a specified dose on specified days
LenvatinibDrug
Administered via oral capsules at a specified dose on specified days
ATRADrug
Administered via oral capsules at a specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 39 months
- Percentage of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to 35 months
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)Time frame: Up to approximately 59 months
- ORR Per RECIST 1.1 With 90% CITime frame: Up to approximately 59 months
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute ( Site 1009)
Los Angeles, California
UCLA Hematology & Oncology ( Site 1004)
Los Angeles, California
Providence Saint John's Health Center ( Site 1010)
Santa Monica, California
University of Colorado, Anschutz Cancer Pavilion ( Site 1012)
Aurora, Colorado
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022)
Baltimore, Maryland
NYU Clinical Cancer Center ( Site 1002)
New York, New York
Duke Cancer Institute ( Site 1005)
Durham, North Carolina
Martha Morehouse Tower ( Site 1020)
Columbus, Ohio
Oregon Health & Science University ( Site 1013)
Portland, Oregon
University of Pennsylvania Abramson Cancer Center ( Site 1008)
Philadelphia, Pennsylvania
West Cancer Center - East Campus ( Site 1014)
Germantown, Tennessee
University of Texas MD Anderson Cancer Center ( Site 1006)
Houston, Texas
Inova Schar Cancer Institute ( Site 1011)
Fairfax, Virginia
Calvary Mater Newcastle-Medical Oncology ( Site 1404)
Waratah, New South Wales, Australia
Melanoma Institute Australia ( Site 1402)
Wollstonecraft, New South Wales, Australia
Tasman Oncology Research Pty Ltd ( Site 1403)
Southport, Queensland, Australia
Fiona Stanley Hospital ( Site 1401)
Murdoch, Western Australia, Australia
A.P.H. Paris, Hopital Saint Louis ( Site 1107)
Paris, France
Hopital La Timone ( Site 1103)
Marseille, Bouches-du-Rhone, France
Hopital Saint Andre ( Site 1108)
Bordeaux, Gironde, France
Institut Claudius Regaud ( Site 1105)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 1101)
Villejuif, Île-de-France Region, France
Centre Hospitalier Lyon Sud ( Site 1102)
Pierre-Bénite, Rhone, France
HaEmek Medical Center ( Site 1703)
Afula, Israel
Rambam Health Care Campus-Oncology ( Site 1704)
Haifa, Israel
Hadassah Ein Karem Jerusalem ( Site 1702)
Jerusalem, Israel
Chaim Sheba Medical Center ( Site 1701)
Ramat Gan, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399)
Milan, Italy
Istituto Europeo di Oncologia ( Site 1301)
Milan, Italy
Istituto Nazionale Tumori Fondazione Pascale ( Site 1302)
Naples, Italy
Istituto Oncologico Veneto IRCCS ( Site 1355)
Padova, Italy
Policlinico Le Scotte - A.O. Senese ( Site 1377)
Siena, Italy
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE-Clinical Trials Unit ( Site 1865)
Port Elizabeth, Eastern Cape, South Africa
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603)
Geneva, Canton of Geneva, Switzerland
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)
Lausanne, Canton of Vaud, Switzerland
Universitaetsspital Zuerich ( Site 1601)
Zuerich Flughafen, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.